Saying Goodbye To The XOMA Royalty PFDs

Ligand Pharmaceuticals will acquire XOMA Royalty for $39.00 per share in cash, valuing the deal at approximately $739 million. XOMA shareholders will also receive a CVR tied to 75% of net proceeds from certain pending litigation, adding potential upside beyond the cash consideration. The transaction is expected to close in Q3 2026 and is described as immediately accretive to LGND EPS.

Analysis

This is structurally better for LGND than the headline spread suggests because the acquisition converts a niche royalty platform into a larger, more diversified cash-flow compounding story. The immediate accretion signal matters: in a market that is still discounting biotech for duration and financing risk, a cash-funded, earnings-accretive deal tends to compress the multiple gap for the acquirer faster than the target arbitrage closes. The bigger second-order effect is that LGND is effectively buying optionality on legal monetization at a discount while removing the market’s uncertainty haircut on XOMA’s standalone royalty portfolio.

For XOMA, the CVR is the key source of trading volatility and likely where the market will misprice value. CVRs tied to litigation outcomes usually trade with a steep probability-weighted discount because the distribution is binary, slow, and information-poor; that creates a potential dislocation between headline deal value and realizable value for holders who need liquidity before the legal process resolves. The timeline also matters: with closing pushed to 2026, the arb is long-duration, exposed to rate volatility, regulatory friction, and any deterioration in litigation recovery prospects.

The main risk to LGND is not the announced premium, but execution and balance-sheet flexibility if the market starts treating this as a template for serial M&A rather than disciplined capital allocation. If the street believes management is using cash flow to buy complexity instead of high-return royalty assets, the multiple could stop expanding even with accretion. For XOMA, the bear case is that the CVR gets marked down repeatedly as the litigation drags, so the stock may trade less like a cash takeout and more like a long-dated special situation with path dependence.

Consensus likely underestimates how much of the value transfer sits in the CVR and how little of it is visible in standard merger-arb models. In other words, the ‘deal premium’ is probably overstated in the stock price, while the real optionality is in legal monetization that may never be fully realized by public-market holders. That asymmetry favors patience on LGND and caution on owning XOMA outright unless you have a view on the litigation itself rather than just the headline spread.

Key Decisions for Investors

• Long LGND on pullbacks over the next 1-3 weeks; the setup is favorable for multiple expansion if the market starts pricing in accretion plus lower standalone uncertainty. Risk/reward improves if the name sells off on broader biotech weakness, since the deal provides an earnings floor.
• Avoid chasing XOMA at the headline price unless you can value the CVR separately; treat it as a long-dated litigation instrument with asymmetric downside if the CVR market assigns a heavy discount. Best entry is only on arb dislocations or forced selling.
• For merger-arb accounts, consider a LGND/XOMA risk-neutral pair only if you can fund the carry through 2026 and hedge legal-process noise; the edge is in financing the duration, not in a quick spread capture.
• Buy LGND calls dated into the expected close window only if implied vol remains modest relative to deal certainty; upside is a rerating on accretion and capital deployment credibility, while downside is limited by deal context unless financing or regulatory issues emerge.